Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung

Cancer

Volumn 79, Issue 3, 1997, Pages 474-481

  Fujisawa, Takehiko ^a   Yamaguchi, Yutaka ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

autologous tumor killing activity; lung carcinoma; prognostic factor; surgery

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CYTOTOXICITY, IMMUNOLOGIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031037304     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970201)79:3<474::AID-CNCR8>3.0.CO;2-I     Document Type: Article

References (28)

1. Vose BM. Specific T-cell-mediated killing of autologous lung tumor cells. Cell Immunol 1980;55:12-9.
2. Vanky F, Peterffy A, Book K, Willems J, Klein E, Klein G. Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course: II. Evaluation of 69 patients with lung carcinoma. Cancer Immunol Immunother 1983; 16:17-22.
3. Holms EC, Golub SH. Immunologic defects in lung cancer patients. J Thorac Cardiovasc Surg 1976;56:362-70.
4. Figarella EF, Morillo F, Bianca I, Bianco NE. Failure of cell mediated effector mechanisms in lung cancer. J Natl Cancer Inst 1984;73:1-6.
5. Vanky F, Klein E, Willems J, Book K, Ivert T, Peterffy A, et al. Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Cancer Immunol Immunother 1986;21:69-76.
6. Uchida A, Kariya Y, Okamoto N, Sugie K, Fujimoto T, Yagita M. Prediction of clinical course by autologous tumor-killing activity in lung cancer patients. J Natl Cancer Inst 1990;82:1697-701.
7. American Joint Committee on Cancer. Manual for staging of cancer. 4th edition. Philadelphia: IB Lippincott, 1992:115-22.
8. The Japan Lung Cancer Society. The General Rule for Clinical and Pathological Record of Lung Cancer. Tokyo: Kanehara Press, 1995:89-121.
9. Robbins SL, Cotran RS. Differentiation and anaplasia. In: Robbins SL, Cotran RS, editors. Pathologic basis of disease. 2nd edition. Philadelphia: WB Saunders, 1979:146-50.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
11. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-200.
12. Cochran AJ, Spilg WGS, Mackie RM, Thomas CE. Postoperative depression of tumor-directed cell-mediated immunity in patients with malignant disease. Br Med J 1972;4:67-70.
13. Vose BM, Moudgil GC. Effect of surgery on tumor-directed leukocyte responses. Br Med J 1975;1:56-8.
14. Heppner GH. In vitro studies on cell-mediated immunity following surgery in mice sensitized to syngeneic mammary tumors, Int J Cancer 1972;9:119-25.
15. Sjögren HO, Hellström I, Bansal SC, Hellström KE. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sci U S A 1971;68:1372-5.
16. Hellström I, Warner GA, Hellström KE, Sjögren HO. Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma. Int J Cancer 1973;11:280-92.
17. House AK, Wisniewski S, Woodings TL. Immunity in colonic tumor patients after operation: determination by leukocyte-migration inhibition. Dis Colon Rectum 1975; 18:100-6.
18. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225s-33s.
19. Sorensen JB, Badsberg JH. Prognostic factors in resected stages I and II adenocarcinoma of the lung. J Thorac Cardiovasc Surg 1990;99:218-26.
20. Uchida A, Moore M. Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor. J Natl Cancer Inst 1984;73:1285-92.
21. Matthews MJ, Kanhouwa S, Pickren J, Robinatte P. Frequency of residual and metastatic tumor in patients under-going curative surgical resection for lung cancer. Cancer Chemother Rep 1973;4:63-4.
22. Stenbygaard LE, Sorensen JB, Olsen JE. Metastatic pattern in adenocarcinoma of the lung: an autopsy study of 137 consecutive patients with complete resection. J Thorac Cardiovasc Surg 1995;110:1130-5.
23. Mountain CF, Gail MH. Surgical adjuvant intrapleural BCG treatment for stage I nonsmall cell lung cancer. J Thorac Cardiovasc Surg 1981;82:649-57.
24. Watanabe Y, Iwa T. Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 1984;53:248-53.
25. Ludwig lung cancer study group. Adverse effect of intrapleural corynebacterium parvum as adjuvant therapy in resected stage I and II nonsmall cell carcinoma of the lung. J Thorac Cardiovasc Surg 1985;89:842-7.
26. Fijisawa T, Yamaguchi Y, Kimura H, Arita M, Baba M, Shiba M. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984;54:663-9.
27. Bhattacharya CM, Foon KA, Kohler H. Anti-idiotype monoclonal antibodies as vaccines for human cancer. Int Rev Immunol 1991;7:289-302.
28. Zeng CQ, Alpert LC, Alpert E. Characterization of a lung-cancer-associated auto-antigen. Int J Cancer 1992; 52:523-9.